Oh, Look, Another Systematic Review on Glioma Immunotherapy

So, apparently, glial brain tumours are still kicking our butts in the neurosurgical arena, and the standard “cut-poison-burn” approach isn’t quite cutting it for the higher-grade party crashers. Enter the shining knight of modern medicine: immunotherapy. Because, you know, our own immune system might just need a little pep talk to tackle those pesky gliomas.

Now, brace yourselves for a groundbreaking approach: a systematic review! And not just any review, but one that’s going to follow the oh-so-riveting PRISMA guidelines. We’re going to dive into the depths of databases like PubMed, Scopus, and a few others that researchers love to name-drop. But hold your horses, we’re only looking at the crème de la crème: English clinical trials. Because who needs diversity in scientific research, right?

Two independent authors, who are surely thrilled about their task, will sift through the data like they’re on a treasure hunt. They’ll be playing with stats, tossing around Cochran’s Q and I2 like confetti, and deciding whether to go with a random-effects meta-analysis or a fixed-effects model based on how homogenous the data feels that day.

And because no research is complete without a little paranoia about bias, we’ll have Begg’s and Egger’s tests, plus Funnel plots to make sure everything’s on the up and up. But don’t worry about the ethical stuff; it’s just a systematic review, no actual humans were poked or prodded in the making of this paper.

So, when all is said and done, this riveting tale of data crunching and meta-analysing will be served up in a peer-reviewed journal for your reading pleasure. Stay tuned for the grand reveal, folks. It’s going to be a wild ride through the land of the obvious and already known. CRD42022373297, remember the number, it’s bound to be as famous as 007.